Developing new drugs to target proteases involved in various diseases
Reprogramming proteases: tackling human diseases with next-generation modulators
This study is looking for new ways to find drugs that can help treat diseases like Alzheimer's and diabetes by focusing on special enzymes called proteases, using smart computer techniques to speed up the process, so patients can get better-targeted treatments faster.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10935951 on NIH RePORTER |
What this research studies
This research focuses on improving the discovery of drugs that can selectively inhibit or activate proteases, which are enzymes involved in many diseases, including Alzheimer's and diabetes. By utilizing machine learning and high-throughput screening, the project aims to identify effective drug candidates based on their functional properties rather than just their binding capabilities. This innovative approach seeks to streamline the drug development process, making it more efficient and predictive. Patients may benefit from new treatments that target specific proteases linked to their conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, adult-onset diabetes, or other conditions related to protease dysfunction.
Not a fit: Patients with conditions unrelated to protease activity may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for diseases like Alzheimer's and diabetes by providing targeted drug options.
How similar studies have performed: Other research has shown promise in using machine learning for drug discovery, indicating that this approach could be effective.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Denard, Carl — University of Florida
- Study coordinator: Denard, Carl
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.